DDInter1340 DDInter465
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amphetamine
Amphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amphetamine
Amphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Pirfenidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Dacomitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Dacomitinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib